Search

Your search keyword '"McMurray, John J.V."' showing total 2,774 results
Start Over Author "McMurray, John J.V."
2,774 results on '"McMurray, John J.V."'

156. Sex Differences in Heart Failure With Improved Ejection Fraction

Author

Pabón, Maria A., Wang, Xiaowen, Lam, Carolyn S.P., O’Meara, Eileen, Vaduganathan, Muthiah, Claggett, Brian L., Foà, Alberto, Lu, Henri, Langkilde, Anna Maria, De Boer, Rudolf A., Desai, Akshay S., Hernandez, Adrian F., Inzucchi, Silvio E., Jhund, Pardeep S., Kosiborod, Mikhail N., Martinez, Felipe A., Shah, Sanjiv J., Petersson, Magnus, McMurray, John J.V., Solomon, Scott D., and Vardeny, Orly

Published
2024
Full Text
View/download PDF

159. High Risk of Stroke in Patients With Worsening Heart Failure, Reduced Ejection Fraction, Coronary Heart Disease and Sinus Rhythm: Risk Prediction Score Analysis From the COMMANDER-HF Trial.

Author

MONZO, LUCA, GIRERD, NICOLAS, FERREIRA, JOÃO PEDRO, LAMIRAL, ZOHRA, ANKER, STEFAN D., CLELAND, JOHN G.F., KONDO, TORU, MCMURRAY, JOHN J.V., LAM, CAROLYN S.P., MEHRA, MANDEEP R., VELDHUISEN, DIRK J. VAN, GREENBERG, BARRY, and ZANNAD, FAIEZ

Abstract

• Clinical settings influence stroke prediction scores in HFrEF with sinus rhythm. • Rivaroxaban is associated with a reduced stroke risk in HFrEF with sinus rhythm and high D-dimer. • The predictive value of stroke risk score should be evaluated further. Patients with heart failure with reduced ejection fraction (HFrEF) and sinus rhythm have a heightened risk of stroke. Whether anticoagulation benefits these patients is uncertain. In this post hoc analysis of the A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction, or Stroke in Participants with Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure (COMMANDER-HF) trial we evaluated how a previously validated risk model consisting of 3 variables (history of prior stroke, insulin-treated diabetes, and N-terminal pro-B-type natriuretic peptide level) would perform, compared with plasma d -dimer, for stroke prediction and estimation of the benefit of low-dose rivaroxaban. Stroke risk and treatment effect were computed across risk score and plasma d -dimer tertiles. Risk score was available in 58% of the COMMANDER-HF population (n = 2928). Over a median follow-up of 512 days (range 342–747 days), 60 patients experienced a stroke (14.6 per 1000 patient-years). The risk model did not identify patients at higher risk of stroke and showed a low overall prognostic performance (C-index = 0.53). The effect of rivaroxaban on stroke was homogeneous across risk score tertiles (P -interaction =.67). Among patients in whom the risk score was estimated, d -dimer was available in 2343 (80%). d -dimer had an acceptable discrimination performance for stroke prediction (C-index = 0.66) and higher plasma d -dimer concentrations were associated with higher rates of stroke (ie, tertile 3 vs tertile 1, hazard ratio 3.65, 95% confidence interval 1.59–8.39, P =.002). Treatment with low-dose rivaroxaban reduced the incidence of stroke in patients at highest risk by d -dimer levels (ie, >515 ng/mL, hazard ratio 0.42, 95% confidence interval 0.18–0.95, P -interaction =.074), without any safety concerns. In our analysis, plasma d -dimer concentrations performed better than a previously described 3-variable risk score for stroke prediction in patients with heart failure with reduced ejection fraction, a recent clinical worsening and sinus rhythm as enrolled in the COMMANDER-HF trial. In these patients, a raised plasma d -dimer concentration identified patients who might benefit most from rivaroxaban. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

160. Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials.

Author

McMurray, John J.V., Docherty, Kieran F., de Boer, Rudolf A., Hammarstedt, Ann, Kitzman, Dalane W., Kosiborod, Mikhail N., Maria Langkilde, Anna, Reicher, Barry, Senni, Michele, Shah, Sanjiv J., Wilderäng, Ulrica, Verma, Subodh, and Solomon, Scott D.

Subjects
*HEART failure, *SODIUM-glucose cotransporter 2 inhibitors, *HEART failure patients, *CLINICAL trials, *DAPAGLIFLOZIN, *VENTRICULAR ejection fraction
Abstract

BACKGROUND: Sodium-glucose cotransporter 2 inhibitors reduce the risk of worsening heart failure (HF) and cardiovascular death in patients with HF irrespective of left ventricular ejection fraction. It is important to determine whether therapies for HF improve symptoms and functional capacity. METHODS: The DETERMINE (Dapagliflozin Effect on Exercise Capacity Using a 6-Minute Walk Test in Patients With Heart Failure) double-blind, placebo-controlled, multicenter trials assessed the efficacy of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on the Total Symptom Score (TSS) and Physical Limitation Scale (PLS) of the Kansas City Cardiomyopathy Questionnaire (KCCQ) and 6-minute walk distance (6MWD) in 313 patients with HF with reduced ejection fraction (DETERMINE-Reduced) and in 504 patients with HF with preserved ejection fraction (DETERMINE-Preserved) with New York Heart Association class II or III symptoms and elevated natriuretic peptide levels. The primary outcomes were changes in the KCCQ-TSS, KCCQ-PLS, and 6MWD after 16 weeks of treatment. RESULTS: Among the 313 randomized patients with HF with reduced ejection fraction, the median placebo-corrected difference in KCCQ-TSS from baseline at 16 weeks was 4.2 (95% CI, 1.0, 8.2; P =0.022) in favor of dapagliflozin. The median placebo-corrected difference in KCCQ-PLS was 4.2 (95% CI, 0.0, 8.3; P =0.058). The median placebo-corrected difference in 6MWD from baseline at 16 weeks was 3.2 meters (95% CI, −6.5, 13.0; P =0.69). In the 504 patients with HF with preserved ejection fraction, the median placebo-corrected 16-week difference in KCCQ-TSS and KCCQ-PLS was 3.2 (95% CI, 0.4, 6.0; P =0.079) and 3.1 (−0.1, 5.4; P =0.23), respectively. The median 16-week difference in 6MWD was 1.6 meters (95% CI, −5.9, 9.0; P =0.67). In an exploratory post hoc analysis of both trials combined (DETERMINE-Pooled), the median placebo-corrected difference from baseline at 16 weeks was 3.7 (1.5, 5.9; P =0.005) for KCCQ-TSS, 4.0 (0.3, 4.9; P =0.036) for KCCQ-PLS, and 2.5 meters (−3.5, 8.4; P =0.50) for 6MWD. CONCLUSIONS: Dapagliflozin improved the KCCQ-TSS in patients with HF with reduced ejection fraction but did not improve KCCQ-PLS or 6MWD. Dapagliflozin did not improve these outcomes in patients with HF with preserved ejection fraction. In a post hoc analysis including all patients across the full spectrum of ejection fraction, there was a beneficial effect of dapagliflozin on KCCQ-TSS and KCCQ-PLS but not 6MWD. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifiers: NCT03877237 and NCT03877224. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

161. Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan.

Author

Butt, Jawad H., McDowell, Kirsty, Kondo, Toru, Desai, Akshay S., Lefkowitz, Martin P., Packer, Milton, Petrie, Mark C., Pfeffer, Marc A., Rouleau, Jean L., Vaduganathan, Muthiah, Zile, Michael R., Jhund, Pardeep S., Køber, Lars, Solomon, Scott, and McMurray, John J.V.

Subjects
BRAIN natriuretic factor, ERYTHROCYTES, HEART failure, VENTRICULAR ejection fraction, VALSARTAN
Abstract

Aims: Red cell distribution width (RDW) is a strong prognostic marker in patients with heart failure (HF) and reduced ejection fraction and other conditions. However, very little is known about its prognostic significance in HF with preserved ejection fraction. We examined the relationship between RDW and outcomes and the effect of sacubitril/valsartan, compared with valsartan, on RDW and clinical outcomes in PARAGON‐HF. Methods and results: PARAGON‐HF enrolled patients with a left ventricular ejection fraction of ≥45%, structural heart disease, and elevated N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP). The primary endpoint was a composite of total HF hospitalizations and cardiovascular deaths. Median RDW at randomization was 14.1% (interquartile range 13.5–15.0%). Patients with higher RDW levels were more often men and had more comorbidity, a higher heart rate and NT‐proBNP concentration, more advanced New York Heart Association class, and worse Kansas City Cardiomyopathy Questionnaire scores. There was a graded relationship between quartiles of RDW at randomization and the primary endpoint, with a significantly higher risk associated with increasing RDW, even after adjustment for NT‐proBNP and other prognostic variables {Quartile 1, reference; Quartile 2, rate ratio 1.03 [95% confidence interval (CI) 0.83 to 1.28]; Quartile 3, 1.25 [1.01 to 1.54]; Quartile 4, 1.70 [1.39 to 2.08]}. This association was seen for each of the secondary outcomes, including cardiovascular and all‐cause death. Compared with valsartan, sacubitril/valsartan reduced RDW at 48 weeks [mean change −0.09 (95% CI −0.15 to −0.02)]. The effect of sacubitril/valsartan vs. valsartan was not significantly modified by RDW levels at randomization. Conclusions: RDW, a routinely available and inexpensive biomarker, provides incremental prognostic information when added to established predictors. Compared with valsartan, sacubitril/valsartan led to a small reduction in RDW. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

162. Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER

Author

Kondo, Toru, primary, Butt, Jawad H., additional, Curtain, James P., additional, Jhund, Pardeep S., additional, Docherty, Kieran F., additional, Claggett, Brian L., additional, Vaduganathan, Muthiah, additional, Bachus, Erasmus, additional, Hernandez, Adrian F., additional, Lam, Carolyn S.P., additional, Inzucchi, Silvio E., additional, Martinez, Felipe A., additional, de Boer, Rudolf A., additional, Kosiborod, Mikhail N., additional, Desai, Akshay S., additional, Køber, Lars, additional, Ponikowski, Piotr, additional, Sabatine, Marc S., additional, Solomon, Scott D., additional, and McMurray, John J.V, additional

Published
2023
Full Text
View/download PDF

163. Use of Win Statistics to Analyze Outcomes in the DAPA-HF and DELIVER Trials

Author

Kondo, Toru, primary, Gasparyan, Samvel B., additional, Jhund, Pardeep S., additional, Bengtsson, Olof, additional, Claggett, Brian L., additional, de Boer, Rudolf A., additional, Hernandez, Adrian F., additional, Inzucchi, Silvio E., additional, Kosiborod, Mikhail N., additional, Køber, Lars, additional, Lam, Carolyn S.P., additional, Langkilde, Anna Maria, additional, Martinez, Felipe A., additional, Petersson, Magnus, additional, Ponikowski, Piotr, additional, Sabatine, Marc S., additional, Shah, Sanjiv J., additional, Sjostrand, Mikaela, additional, Wilderang, Ulrica, additional, Vaduganathan, Muthiah, additional, Solomon, Scott D., additional, and McMurray, John J.V., additional

Published
2023
Full Text
View/download PDF

164. Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan

Author

Butt, Jawad H., primary, McDowell, Kirsty, additional, Kondo, Toru, additional, Desai, Akshay S., additional, Lefkowitz, Martin P., additional, Packer, Milton, additional, Petrie, Mark C., additional, Pfeffer, Marc A., additional, Rouleau, Jean L., additional, Vaduganathan, Muthiah, additional, Zile, Michael R., additional, Jhund, Pardeep S., additional, Køber, Lars, additional, Solomon, Scott, additional, and McMurray, John J.V., additional

Published
2023
Full Text
View/download PDF

165. Calcium channel blocker and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction

Author

Matsumoto, Shingo, primary, Kondo, Toru, additional, Yang, Mingming, additional, Campbell, Ross T, additional, Docherty, Kieran F., additional, de Boer, Rudolf A., additional, Desai, Akshay S., additional, Lam, Carolyn S.P., additional, Packer, Milton, additional, Pitt, Bertram, additional, Rouleau, Jean L., additional, Vaduganathan, Muthiah, additional, Zannad, Faiez, additional, Zile, Michael R., additional, Solomon, Scott D., additional, Jhund, Pardeep S., additional, and McMurray, John J.V., additional

Published
2023
Full Text
View/download PDF

166. Impact of COVID‐19 in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction Enrolled in the DELIVER Trial

Author

Bhatt, Ankeet S., primary, Kosiborod, Mikhail N., additional, Claggett, Brian L., additional, Miao, Zi Michael, additional, Vaduganathan, Muthiah, additional, Lam, Carolyn S.P., additional, Hernandez, Adrian F., additional, Martinez, Felipe A., additional, Inzucchi, Silvio E, additional, Shah, Sanjiv J., additional, de Boer, Rudolf A., additional, Jhund, Pardeep S., additional, Desai, Akshay S., additional, Fang, James C., additional, Han, Yaling, additional, Comin‐Colet, Josep, additional, Drożdż, Jarosław, additional, Vardeny, Orly, additional, Merkely, Bela, additional, Lindholm, Daniel, additional, Peterson, Magnus, additional, Langkilde, Anna Maria, additional, McMurray, John J.V., additional, and Solomon, Scott D., additional

Published
2023
Full Text
View/download PDF

167. Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER

Author

Butt, Jawad H., primary, Lu, Henri, additional, Kondo, Toru, additional, Bachus, Erasmus, additional, de Boer, Rudolf A., additional, Inzucchi, Silvio E., additional, Jhund, Pardeep S., additional, Kosiborod, Mikhail N., additional, Lam, Carolyn S.P., additional, Martinez, Felipe A., additional, Vaduganathan, Muthiah, additional, Solomon, Scott D., additional, and McMurray, John J.V., additional

Published
2023
Full Text
View/download PDF

168. Contemporary Use and Implications of Beta-blockers in Patients with HFmrEF or HFpEF: the DELIVER Trial

Author

Peikert, Alexander, primary, Bart, Bradley A., additional, Vaduganathan, Muthiah, additional, Claggett, Brian L., additional, Kulac, Ian J., additional, Kosiborod, Mikhail N., additional, Desai, Akshay S., additional, Jhund, Pardeep S., additional, Lam, Carolyn S.P., additional, Inzucchi, Silvio E., additional, Martinez, Felipe A., additional, de Boer, Rudolf A., additional, Hernandez, Adrian F., additional, Shah, Sanjiv J., additional, Petersson, Magnus, additional, Langkilde, Anna Maria, additional, McMurray, John J.V., additional, Solomon, Scott D., additional, and Vardeny, Orly, additional

Published
2023
Full Text
View/download PDF

169. Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure

Author

Kondo, Toru, primary, Wang, Xiaowen, additional, Yang, Mingming, additional, Jhund, Pardeep S., additional, Claggett, Brian L., additional, Vaduganathan, Muthiah, additional, Hernandez, Adrian F., additional, Lam, Carolyn S.P., additional, Inzucchi, Silvio E., additional, Martinez, Felipe A., additional, de Boer, Rudolf A., additional, Kosiborod, Mikhail N., additional, Desai, Akshay S., additional, Køber, Lars, additional, Ponikowski, Piotr, additional, Sabatine, Marc S., additional, Langkilde, Anna Maria, additional, Petersson, Magnus, additional, Zaozerska, Natalia, additional, Bachus, Erasmus, additional, Solomon, Scott D., additional, and McMurray, John J.V., additional

Published
2023
Full Text
View/download PDF

170. Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trial

Author

Pabon, Maria, primary, Claggett, Brian L., additional, Wang, Xiaowen, additional, Miao, Zi Michael, additional, Chatur, Safia, additional, Bhatt, Ankeet S., additional, Vaduganathan, Muthiah, additional, Fang, James C., additional, Desai, Akshay S, additional, Jhund, Pardeep, additional, Martinez, Felipe, additional, de Boer, Rudolf A., additional, Kosiborod, Mikhail N., additional, Lam, Carolyn S.P., additional, Shah, Sanjiv J., additional, Hernandez, Adrian F., additional, McMurray, John J.V., additional, Solomon, Scott D., additional, and Vardeny, Orly, additional

Published
2023
Full Text
View/download PDF

171. Global Comparison of Readmission Rates for Patients With Heart Failure

Author

Foroutan, Farid, primary, Rayner, Daniel G., additional, Ross, Heather J., additional, Ehler, Tamara, additional, Srivastava, Ananya, additional, Shin, Sheojung, additional, Malik, Abdullah, additional, Benipal, Harsukh, additional, Yu, Clarissa, additional, Alexander Lau, Tsz Hin, additional, Lee, Joshua G., additional, Rocha, Rodolfo, additional, Austin, Peter C., additional, Levy, Daniel, additional, Ho, Jennifer E., additional, McMurray, John J.V., additional, Zannad, Faiez, additional, Tomlinson, George, additional, Spertus, John A., additional, and Lee, Douglas S., additional

Published
2023
Full Text
View/download PDF

173. Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureGrupo de Trabajo de la Sociedad Europea de Cardiología (ESC) de diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónicaDesarrollada con la colaboración especial de la Heart Failure Association (HFA) de la ESC

Author

McDonagh, Theresa A., Metra, Marco, Adamo, Marianna, Gardner, Roy S., Baumbach, Andreas, Böhm, Michael, Burri, Haran, Butler, Javed, Čelutkienė, Jelena, Chioncel, Ovidiu, Cleland, John G.F., Coats, Andrew J.S., Crespo-Leiro, María G., Farmakis, Dimitrios, Gilard, Martine, Heyman, Stephane, Hoes, Arno W., Jaarsma, Tiny, Jankowska, Ewa A., Lainscak, Mitja, Lam, Carolyn S.P., Lyon, Alexander R., McMurray, John J.V., Mebazaa, Alexandre, Mindham, Richard, Muneretto, Claudio, Francesco Piepoli, Massimo, Price, Susanna, Rosano, Giuseppe M.C., Ruschitzka, Frank, and Skibelund, Anne Kathrine

Published
2022
Full Text
View/download PDF

177. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials

Author

Fitter, Heather D., Illoh, Kachikwu, Cavanaugh, Kenneth J., Jr., Scirica, Benjamin M., Irony, Ilan, Brown Kichline, Rachel E., Levine, Jonathan G., Park, Anna, Sacks, Leonard, Szarfman, Ana, Unger, Ellis F., Wachter, Lori Ann, Zuckerman, Bram, Mitchel, Yale, Peddicord, Douglas, Shook, Thomas, Kisler, Bron, Jaffe, Charles, Bartley, Rhonda, DeMets, David L., Mencini, MariJo, Janning, Cheri, Bai, Steve, Lawrence, John, D’Agostino, Ralph B., Sr., Pocock, Stuart J., Hicks, Karen A., Mahaffey, Kenneth W., Mehran, Roxana, Nissen, Steven E., Wiviott, Stephen D., Dunn, Billy, Solomon, Scott D., Marler, John R., Teerlink, John R., Farb, Andrew, Morrow, David A., Targum, Shari L., Sila, Cathy A., Thanh Hai, Mary T., Jaff, Michael R., Joffe, Hylton V., Cutlip, Donald E., Desai, Akshay S., Lewis, Eldrin F., Gibson, C. Michael, Landray, Martin J., Lincoff, A. Michael, White, Christopher J., Brooks, Steven S., Rosenfield, Kenneth, Domanski, Michael J., Lansky, Alexandra J., McMurray, John J.V., Tcheng, James E., Steinhubl, Steven R., Burton, Paul, Mauri, Laura, O’Connor, Christopher M., Pfeffer, Marc A., Hung, H.M. James, Stockbridge, Norman L., Chaitman, Bernard R., and Temple, Robert J.

Published
2018
Full Text
View/download PDF

185. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF

Author

Jhund, Pardeep S., Solomon, Scott D., Docherty, Kieran F., Heerspink, Hiddo J.L., Anand, Inder S., Böhm, Michael, Chopra, Vijay, de Boer, Rudolf A., Desai, Akshay S., Ge, Junbo, Kitakaze, Masafumi, Merkley, Bela, OʼMeara, Eileen, Shou, Morten, Tereshchenko, Sergey, Verma, Subodh, Vinh, Pham Nguyen, Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Martinez, Felipe A., Ponikowski, Piotr, Sabatine, Marc S., Bengtsson, Olof, Langkilde, Anna Maria, Sjöstrand, Mikaela, and McMurray, John J.V.

Published
2021
Full Text
View/download PDF

186. Knowledge about self‐efficacy and outcomes in patients with heart failure and reduced ejection fraction

Author

Yang, Mingming, primary, Kondo, Toru, additional, Adamson, Carly, additional, Butt, Jawad H., additional, Abraham, William T., additional, Desai, Akshay S., additional, Jering, Karola S., additional, Køber, Lars, additional, Kosiborod, Mikhail N., additional, Packer, Milton, additional, Rouleau, Jean L., additional, Solomon, Scott D., additional, Vaduganathan, Muthiah, additional, Zile, Michael R., additional, Jhund, Pardeep S., additional, and McMurray, John J.V., additional

Published
2023
Full Text
View/download PDF

189. Changes in mid‐regional pro‐adrenomedullin during treatment with sacubitril/valsartan

Author

Myhre, Peder L., primary, Liu, Yuxi, additional, Kulac, Ian J., additional, Claggett, Brian L., additional, Prescott, Margaret F., additional, Felker, G. Michael, additional, Butler, Javed, additional, Piña, Ileana L., additional, Rouleau, Jean L., additional, Zile, Michael R., additional, McMurray, John J.V., additional, Ward, Jonathan H., additional, Solomon, Scott D., additional, and Januzzi, James L., additional

Published
2023
Full Text
View/download PDF

190. Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: A subgroups analysis from the EMPHASIS‐HF trial

Author

Monzo, Luca, primary, Girerd, Nicolas, additional, Duarte, Kevin, additional, Ferreira, João Pedro, additional, McMurray, John J.V., additional, van Veldhuisen, Dirk J., additional, Swedberg, Karl, additional, Pocock, Stuart J., additional, Pitt, Bertram, additional, and Zannad, Faiez, additional

Published
2023
Full Text
View/download PDF

191. Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with HFrEF and HFpEF

Author

Yang, Mingming, primary, Kondo, Toru, additional, Adamson, Carly, additional, Butt, Jawad H., additional, Abraham, William T., additional, Desai, Akshay S., additional, Jering, Karola S., additional, Køber, Lars, additional, Kosiborod, Mikhail N., additional, Packer, Milton, additional, Rouleau, Jean L., additional, Solomon, Scott D., additional, Vaduganathan, Muthiah, additional, Zile, Michael R., additional, Jhund, Pardeep S., additional, and McMurray, John J.V., additional

Published
2023
Full Text
View/download PDF

192. Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure

Author

Docherty, Kieran F., primary, McDowell, Kirsty, additional, Welsh, Paul, additional, Osmanska, Joanna, additional, Anand, Inder, additional, de Boer, Rudolf A., additional, Køber, Lars, additional, Kosiborod, Mikhail N., additional, Martinez, Felipe A., additional, O’Meara, Eileen, additional, Ponikowski, Piotr, additional, Schou, Morten, additional, Berg, David D., additional, Sabatine, Marc S., additional, Morrow, David A., additional, Jarolim, Petr, additional, Hammarstedt, Ann, additional, Sjöstrand, Mikaela, additional, Langkilde, Anna Maria, additional, Solomon, Scott D., additional, Sattar, Naveed, additional, Jhund, Pardeep S., additional, and McMurray, John J.V., additional

Published
2023
Full Text
View/download PDF

193. Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: Insights from the DELIVER trial

Author

Chatur, Safia, primary, Cunningham, Jonathan W., additional, Vaduganathan, Muthiah, additional, Mc Causland, Finnian R., additional, Claggett, Brian L., additional, Desai, Akshay S., additional, Miao, Zi Michael, additional, Jhund, Pardeep S., additional, de Boer, Rudolf A., additional, Hernandez, Adrian F., additional, Inzucchi, Silvio E., additional, Kosiborod, Mikhail N., additional, Lam, Carolyn S.P., additional, Martinez, Felipe A., additional, Shah, Sanjiv J., additional, Petersson, Magnus, additional, Langkilde, Anna Maria, additional, McMurray, John J.V., additional, and Solomon, Scott D., additional

Published
2023
Full Text
View/download PDF

194. Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant‐level pooled analysis from the DAPA‐HF and DELIVER trials

Author

Bhatt, Ankeet S., primary, Kosiborod, Mikhail N., additional, Vaduganathan, Muthiah, additional, Claggett, Brian L., additional, Miao, Z. Michael, additional, Kulac, Ian J., additional, Lam, Carolyn S.P., additional, Hernandez, Adrian F., additional, Martinez, Felipe, additional, Inzucchi, Silvio E, additional, Shah, Sanjiv J., additional, de Boer, Rudolf A., additional, Jhund, Pardeep S., additional, Desai, Akshay S., additional, Petersson, Magnus, additional, Langkilde, Anna Maria, additional, McMurray, John J.V., additional, and Solomon, Scott D., additional

Published
2023
Full Text
View/download PDF

196. The Effect of Sacubitril/Valsartan on Left Ventricular Myocardial Deformation in Heart Failure with Preserved Ejection Fraction (PARAMOUNT trial)

Author

BIERING-SØRENSEN, TOR, primary, LASSEN, MATS C. HØJBJERG, additional, SHAH, AMIL, additional, CLAGGETT, BRIAN, additional, ZILE, MICHAEL, additional, PIESKE, BURKERT, additional, PIESKE-KRAIGHER, ELISABETH, additional, VOORS, ADRIAAN, additional, SHI, VICTOR, additional, LEFKOWITZ, MARTIN, additional, PACKER, MILTON, additional, MCMURRAY, JOHN J.V., additional, and SOLOMON, SCOTT D., additional

Published
2023
Full Text
View/download PDF

197. Effects of Dapagliflozin on Heart Failure Hospitalizations According to Severity of Inpatient Course: Insights from DELIVER and DAPA‐HF

Author

Chatur, Safia, primary, Kondo, Toru, additional, Claggett, Brian L., additional, Docherty, Kieran, additional, Miao, Zi Michael, additional, Desai, Akshay S., additional, Jhund, Pardeep S., additional, de Boer, Rudolf A., additional, Hernandez, Adrian F., additional, Inzucchi, Silvio E., additional, Kosiborod, Mikhail N, additional, Lam, Carolyn S. P., additional, Martinez, Felipe A., additional, Shah, Sanjiv J., additional, Petersson, Magnus, additional, Langkilde, Anna Maria, additional, McMurray, John J.V., additional, Solomon, Scott D., additional, and Vaduganathan, Muthiah, additional

Published
2023
Full Text
View/download PDF

198. Dapagliflozin and Anemia in Patients with Chronic Kidney Disease

Author

Koshino, Akihiko, primary, Schechter, Meir, additional, Chertow, Glenn M., additional, Vart, Priya, additional, Jongs, Niels, additional, Toto, Robert D., additional, Rossing, Peter, additional, Correa-Rotter, Ricardo, additional, McMurray, John J.V., additional, Górriz, Jose Luis, additional, Isidto, Rey, additional, Kashihara, Naoki, additional, Langkilde, Anna Maria, additional, Wheeler, David C., additional, and Heerspink, Hiddo J.L., additional

Published
2023
Full Text
View/download PDF

199. Clinical characteristics of HFrEF patients with rare pathogenic variants in DCM ‐associated genes: a subgroup analysis of the PARADIGM‐HF trial

Author

Barat, Ana, primary, Chen, Chien‐Wei, additional, Patel‐Murray, Natasha, additional, McMurray, John J.V., additional, Packer, Milton, additional, Solomon, Scott D., additional, Desai, Akshay S., additional, Rouleau, Jean L., additional, Zile, Michael R., additional, Attari, Zenab, additional, Zhang, Cong, additional, Xu, Huilei, additional, Hartman, Nicole, additional, Hon, Claudia, additional, Healey, Margaret, additional, Chutkow, William, additional, O'Donnell, Christopher J., additional, Jacob, Jaison, additional, Lefkowitz, Marty, additional, Mendelson, Michael M., additional, Wandel, Simon, additional, Yates, Denise, additional, and Gimpelewicz, Claudio, additional

Published
2023
Full Text
View/download PDF

200. Incremental prognostic value of biomarkers in PARADIGM‐HF

Author

McDowell, Kirsty, primary, Campbell, Ross, additional, Simpson, Joanne, additional, Cunningham, Jonathan W., additional, Desai, Akshay S., additional, Jhund, Pardeep S, additional, Lefkowitz, Martin P., additional, Rouleau, Jean L., additional, Swedberg, Karl, additional, Zile, Michael R., additional, Solomon, Scott D., additional, Packer, Milton, additional, and McMurray, John J.V., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results